BioCina and NovaCina to Partner on Drug Substance and Product Solutions for Biologics

Published on: 

The partnership will allow for both companies to provide end-to-end biopharmaceutical manufacturing solutions.

BioCina, a biologics contract development and manufacturing organization (CDMO) and NovaCina, a global fill-and-finish CDMO, have announced a partnership to offer integrated drug substance and drug product solutions for biologics developers. This will allow BioCina to provide fill/finish services while converting drug substances produced at its Adelaide, South Australia, facilities into drug product at NovaCina’s facilities in Perth, Australia. This collaboration aims to provide end-to-end biopharmaceutical manufacturing solutions.

BioCina specializes in CDMO services such as cell line development, process development, and current good manufacturing practice clinical and commercial manufacturing for microbial, plasmid DNA, and messenger RNA modalities. It plans to establish a second site alongside its Adelaide facility, which was once a Pfizer facility, that will focus on mammalian Parkinson’s disease and large-scale manufacturing. NovaCina focuses on clinical and commercial fill/finish experience, working alongside regulatory bodies for its services, which include development, manufacturing, packaging, labeling, and stability studies.


“BioCIna is excited to partner with NovaCina, integrating our globally recognized expertise in clinical and commercial process development and drug substance manufacturing with their … drug product services,” said Mark W. Womack, BioCina’s CEO, in a press release,

Source: BioCina